Phase 2 N=58 Daily Vitamin D for Sickle-cell Respiratory Complications
Sickle Cell Disease · Anemia, Sickle Cell · Anemia, Hemolytic, Congenital
Primary: Annual Rate of Respiratory Events — 3.3; 3.3; 3.4; 3.2 Respiratory events per year
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=822 Mobile Health and COVID-19
Anxiety Depression
Primary: Everyday Impairment — 15.65; 15.47; 12.74; 13.23 Scores on a scale
Phase 3 N=18 Mepolizumab in Chronic Obstructive Pulmonary Diseases (COPD) With Eosinophilic Bronchitis
Chronic Obstructive Pulmonary Diseases · Chronic Airways Limitation · Bronchitis
Primary: Percentage Decrease of Sputum Eosinophils From Baseline to End of Therapy (6 Months) — 11.28; 7.07 percentage
N/A N=60 Adherence Connection for Counseling, Education, and Support (ACCESS) II
HIV Infections
Primary: Self-Reported ART Adherence — 56.67; 58.7 Percentage of successful doses
N/A N=859 Diabetes Management Intervention For South Asians
HbA1c · Diabetes
Primary: Percentage of Participants Who Had at Least a 0.5% Reduction in HbA1c From Baseline 6 Months — 32.1; 35.2 Percentage of participants
N/A N=974 Integrated Community-Clinical Linkage Model to Promote Weight Loss Among South Asians With Pre-Diabetes
Pre Diabetes · Weight Loss
Primary: Percentage of Participants Who Lost at Least 5% of Body Weight Between Baseline and Month 6 — 11; 19 Percentage of participants
Phase 4 N=210 Health Systems Reach Interventions Project
Smoking, Cigarette · Smoking Cessation
Primary: Number of Participants Who Initiate Treatment Over 1 Year of Study Enrollment — 0; 2; 1; 0 Participants
Phase 2 N=10 Imaging Evaluation of PLN-74809 in Participants With IPF (PLN-74809)
Idiopathic Pulmonary Fibrosis
Primary: Primary Outcome — -0.0147; 0.0740 Unitless
N/A N=14 Pancreatic Endotherapy for Refractory Chronic Pancreatitis
Pancreatic Duct Stone · Pancreatic Duct Stricture · Pancreatic Duct Dilatation
Primary: Percent Change in Average Daily Pain Score on the Numeric Rating Scale — -36.6; -53.7 Percent Change
N/A N=508 Enhancing Cancer Prevention and Control Pathways-Native Health Initiative
Cancer, Breast · Cancer, Colon · Cancer, Cervix
Primary: Aim 3, Focus Groups, Descriptive: Knowledge, Barriers and Support, and Communication About Breast, Cervix, and Colorectal Cancers — 85; 85; 85; 85 Participants
N/A N=260 Investigational Extended Wear Insulin Infusion Set in People With Type 1 Diabetes
Type1diabetes
Primary: 7 Day Survival of Infusion Set for Primary Outcome Measure - Humalog — 95 percentage of infusion set wears — p=<0.001
Phase 2 N=12 Romosozumab in Women With Chronic SCI
Osteoporosis · Bone Loss · Osteopenia, Osteoporosis
Primary: Change in Integral vBMC at the Knee (Distal Femur) — -0.78 g
Phase 2 N=46 Tislelizumab in Participants With Relapsed or Refractory Classical Hodgkin Lymphoma
Classical Hodgkin Lymphoma
Primary: Overall Response Rate (ORR) — 64.3; 64.5; 64.4 Percentage of Participants — p=0.0044
Phase 2 N=146 A Study of CLE-100 (Oral Esketamine) in Addition to Standard Antidepressant Drug for Major Depressive Disorder - CLEO Study
Adjunctive Treatment of Major Depressive Disorder
Primary: Part B - Change From Baseline in Montgomery-Asberg Depression Rating Scale (MADRS) Score — -10.72; -9.46 units on a scale — p=0.46
N/A N=98 Rapid Diagnostic Assay for Gonorrhea and Chlamydia
Urethritis · Cervicitis · Sexually Transmitted Infections
Primary: Mean Antibiotic Days of Therapy (DOT) Administered Per Patient With Symptomatic Urethritis or Cervicitis — 7; 1 Antibiotic days of therapy (DOT) — p=0.053